Is a powdered corticosteroid inhaler such as the Symbicort Turbohaler (budesonide/formoterol) better than a metered‑dose inhaler with a spacer for a patient with persistent dry, itchy throat and cough?

Switching to a Metered-Dose Inhaler with Spacer is Better for Persistent Dry, Itchy Throat and Cough

For patients experiencing persistent dry, itchy throat and cough with a dry powder inhaler like Symbicort Turbuhaler, switching to a metered-dose inhaler (MDI) with a spacer device is the recommended approach to resolve these local irritant symptoms. 1

Understanding the Problem

Local Irritation from Dry Powder Inhalers

• Dysphonia and throat irritation from inhaled corticosteroids are thought to be caused by laryngeal edema, mucosal thickening, or possibly myopathy from local drug deposition 1
• Dry powder inhalers deposit medication directly on the oropharyngeal mucosa, which can cause local irritation, coughing, and throat discomfort 2
• These symptoms are generally intermittent but can be persistent in some patients, significantly affecting quality of life 1

The Solution: MDI with Spacer Device

Why MDI with Spacer is Superior for This Problem

• Changing from a dry-powder inhaler to a metered-dose inhaler with spacer typically resolves dysphonia and throat irritation 1
• Spacers (valved holding chambers) markedly reduce oropharyngeal deposition of inhaled corticosteroids, decreasing local side effects like thrush and throat irritation 1
• The spacer allows the medication to be delivered more effectively to the lungs while reducing the amount deposited in the throat and mouth 1

Equivalent Therapeutic Efficacy

• There are no clinically meaningful differences in bronchoprotective effects between dry powder inhalers and hydrofluoroalkane-propelled metered-dose inhalers when used correctly 1
• When properly used, MDIs deposit 20-30% of the dose in the lungs, and spacers markedly increase this percentage 1
• Studies comparing budesonide via Turbuhaler versus MDI with spacer showed equivalent efficacy for asthma control parameters (FEV1, evening PEF, histamine PC20) 2, 3

Clinical Algorithm for Managing This Problem

Step 1: Confirm the Diagnosis

• Verify that the throat symptoms began or worsened after starting the dry powder inhaler 1
• Rule out other causes: oral candidiasis (thrush), gastroesophageal reflux, or inadequate asthma control 1

Step 2: Switch Delivery Device

• Change from Symbicort Turbuhaler to an equivalent MDI formulation with a valved holding chamber (spacer) 1
• Use the same total daily dose of budesonide/formoterol when switching devices 3
• Ensure proper MDI technique: slow inhalation (30 L/min or 3-5 seconds), followed by 10-second breath-hold 4

Step 3: Additional Measures

• Instruct the patient to rinse mouth and gargle after each use to further reduce oropharyngeal deposition 4
• Spit out the rinse water rather than swallowing to minimize systemic absorption 4
• Consider temporary cessation of the medication if symptoms are severe, though this is rarely necessary with device switching 1

Step 4: Reassess

• Symptoms typically resolve within days to weeks after switching to MDI with spacer 1
• If symptoms persist despite proper MDI/spacer technique, consider alternative diagnoses or changing the specific corticosteroid formulation 1

Important Caveats

Device Selection Considerations

• Patients should initially be treated with a metered-dose inhaler as first-line 5
• If patients cannot coordinate MDI technique, a large volume spacer device should be added 5
• Dry powder inhalers are appropriate alternatives for patients who cannot use MDI with spacer due to portability concerns during the day 5

Spacer Device Maintenance

• Rinse plastic valved holding chambers once monthly with low-concentration household dishwashing detergent (1:5000 or drops per cup of water) and let drip dry 4
• This reduces static charge and enhances drug delivery to the lungs 4

Not a Dose Equivalency Issue

• The problem is not about therapeutic equivalence between devices—both deliver medication effectively 1
• The issue is specifically about local oropharyngeal side effects, which are device-dependent 1, 2
• One study showed patients experienced significantly fewer coughs in the 5 minutes after steroid inhalation with Turbuhaler versus MDI, but this was comparing MDI without optimal spacer use 2

When Spacers Are Essential

• Spacers are particularly important for reducing local side effects from inhaled corticosteroids 1
• They are also critical for patients with poor MDI coordination technique 5, 4
• For children under 4 years, face masks with spacers are required 4